Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

simvastatin

- PMLiVE

Coronavirus outbreak escalation could impact drug supply chain

Concerns raised that the virus could cause shortages

- PMLiVE

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Final decision due by 18 October

- PMLiVE

Esperion gets FDA thumbs up for cholesterol drug Nexletol

Big comeback after previous trial fail

- PMLiVE

Immutep spikes on trial of its LAG-3 drug with Keytruda

Impressive mid-stage results in NSCLC and HNSCC

- PMLiVE

Merck’s Ebola vaccine wins approval in four African countries

Follows approvals in US and Europe last year

EISAI

Eisai agrees to pull obesity drug Belviq after safety alert

Weight-loss drug linked to increased risk of cancer

- PMLiVE

Merck chases Roche with triple-negative breast cancer data for Keytruda

Data demonstrated a delay in disease progression or death

- PMLiVE

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

- PMLiVE

Merck spins off low-growth drugs in a ‘purposeful shift’ of focus

Fourth quarter results overshadowed by spin off announcement

- PMLiVE

Merck gets Alzheimer’s label claim for insomnia drug Belsomra

Alzheimer's patients typically experience poor sleep

- PMLiVE

FDA accepts priority review for Merck’s antibiotic combo Recarbrio

If approved would provide new option for hard-to-treat infections

Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603

Onyx Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links